FGFs and metabolism

Current Opinion in Pharmacology

Volumn 9, Issue 6, 2009, Pages 805-810

  Kharitonenkov, Alexei ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; GROWTH FACTOR; UNCLASSIFIED DRUG;

BILE ACID METABOLISM; DIABETES MELLITUS; DRUG MECHANISM; FATTY LIVER; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; METABOLIC REGULATION; NONHUMAN; OBESITY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VITAMIN D METABOLISM;

ANIMALS; DRUG DELIVERY SYSTEMS; FIBROBLAST GROWTH FACTORS; HUMANS; METABOLIC DISEASES; METABOLISM;

EID: 70449506753     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.07.001     Document Type: Review

References (59)

1. Nishimura T., Utsunomiya Y., Hoshikawa M., Ohuchi H., and Itoh N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1444 (1999) 148-151
2. Tomlinson E., Fu L., John L., Hultgren B., Huang X., Renz M., Stephan J.P., Tsai S.P., Powell-Braxton L., French D., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143 (2002) 1741-1747. This work provides functional and mechanistic insights into FGF19 metabolic actions.
3. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., Luo G., Jones S.A., Goodwin B., Richardson J.A., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 4 (2005) 217-225. This study demonstrates the existence of FGF15/FGF19 gut-to-liver axis of tissue crosscommunication.
4. Nishimura T., Nakatake Y., Konishi M., and Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492 (2000) 203-206
5. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 115 (2005) 1627-1635. This work identifies FGF21 as a critical metabolic regulator.
6. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26 (2000) 345-348. This study describes cloning of FGF23 based on its role in ADHR.
7. Goetz R., Beenken A., Ibrahimi O.A., Kalinina J., Olsen S.K., Eliseenkova A.V., Xu C., Neubert T.A., Zhang F., Linhardt R.J., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27 (2007) 3417-3428
8. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997) 45-51. This study reports on the identification of Klotho and functional consequences of its deficiency.
9. Ito S., Kinoshita S., Shiraishi N., Nakagawa S., Sekine S., Fujimori T., and Nabeshima Y.I. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev 98 (2000) 115-119
10. Lin B.C., Wang M., Blackmore C., and Desnoyers L.R. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 282 (2007) 27277-27284
11. Kharitonenkov A., Dunbar J.D., Bina H.A., Bright S., Moyers J.S., Zhang C., Ding L., Micanovic R., Mehrbod S.F., Knierman M.D., et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 215 (2008) 1-7. This work reveals βKlotho as structural part of FGF21 receptor.
12. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., Baum M.G., Schiavi S., Hu M.C., Moe O.W., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281 (2006) 6120-6123. This work shows the role of Klotho in FGF23 signaling.
13. Xie M.H., Holcomb I., Deuel B., Dowd P., Huang A., Vagts A., Foster J., Liang J., Brush J., Gu Q., et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11 (1999) 729-735
14. Wu X., Ge H., Gupte J., Weiszmann J., Shimamoto G., Stevens J., Hawkins N., Lemon B., Shen W., Xu J., et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem 282 (2007) 29069-29072
15. Wu X., Lemon B., Li X., Gupte J., Weiszmann J., Stevens J., Hawkins N., Shen W., Lindberg R., Chen J.L., et al. C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J Biol Chem 283 (2008) 33304-33309
16. Ladher R.K., Anakwe K.U., Gurney A.L., Schoenwolf G.C., and Francis-West P.H. Identification of synergistic signals initiating inner ear development. Science 290 (2000) 1965-1967
17. Fu L., John L.M., Adams S.H., Yu X.X., Tomlinson E., Renz M., Williams P.M., Soriano R., Corpuz R., Moffat B., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145 (2004) 2594-2603
18. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C., Chen Y., Moller D.E., and Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149 (2008) 6018-6027. This work provides the functional and mechanistic insights into FGF21 in vivo action.
19. Huang X., Yu C., Jin C., Yang C., Xie R., Cao D., Wang F., and McKeehan W.L. Forced expression of hepatocyte-specific fibroblast growth factor-21 delays initiation of chemically-induced hepatocarcinogenesis. Mol Carcinog 45 (2006) 934-942. This work reports on the nonmitogenic character of FGF21 overexpression in mice.
20. Nicholes K., Guillet S., Tomlinson E., Hillan K., Wright B., Frantz G.D., Pham T.A., Dillard-Telm L., Tsai S.P., Stephan J.P., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160 (2002) 2295-2307
21. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., and Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006) 770-774. This work demonstrates Klotho as a cofactor for FGF23 phosphaturic activity.
22. Yu C., Wang F., Jin C., Huang X., and McKeehan W.L. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem 280 (2005) 17707-17714
23. Huang X., Yang C., Luo Y., Jin C., Wang F., and McKeehan W.L. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 56 (2007) 2501-2510. This study points toward FGFRs beyond FGFR4 to support FGF19 metabolic actions.
24. Lundåsen T., Gälman C., Angelin B., and Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260 (2006) 530-536
25. Wente W., Efanov A.M., Brenner M., Kharitonenkov A., Köster A., Sandusky G.E., Sewing S., Treinies I., Zitzer H., and Gromada J. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55 (2006) 2470-2478
26. Wang H., Qiang L., and Farmer S.R. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 28 (2008) 188-200
27. Izumiya Y., Bina H.A., Ouchi N., Akasaki Y., Kharitonenkov A., and Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett 582 (2008) 3805-3810
28. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., and Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5 (2007) 426-437. This study describes FGF21 as a PPARα-regulated ketogenic factor.
29. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., Elmquist J.K., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5 (2007) 415-425
30. Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K.P., Goetz R., Eliseenkova A.V., Mohammadi M., and Kuro-o M. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 104 (2007) 7432-7437
31. Micanovic R., Raches D.W., Dunbar J.D., Driver D.A., Bina H.A., Dickinson C.D., and Kharitonenkov A. Different roles of N- and C-termini in the functional activity of FGF21. J Cell Phys 219 (2009) 227-234
32. Yie J., Hecht R., Patel J., Stevens J., Wang W., Hawkins N., Steavenson S., Smith S., Winters D., Fisher S., et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 583 (2009) 19-24
33. Kharitonenkov A., and Shanafelt A.B. FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs 10 (2009) 359-364. Comprehensive review focusing on FGF21 pharmacology and mechanism of action.
34. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., Vonderfecht S.N., Hecht R., Li L., Lindberg R.A., et al. FGF21 reverses hepatic steatosis, increases energy expenditure and improves insulin sensitivity in diet-induced obese mice. Diabetes 58 (2009) 250-259. This study reports FGF21 ability to reverse obesity and hepatosteatosis.
35. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., Hansen B.C., Shanafelt A.B., and Etgen G.J. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148 (2007) 774-781. This study analyzes FGF21 pharmacology in nonhuman primates.
36. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.G., Liu F., Wong R.L., Chow W.S., Tso A.W., Lam K.S., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57 (2008) 1246-1253
37. Chen W.W., Li L., Yang G.Y., Li K., Qi X.Y., Zhu W., Tang Y., Liu H., and Boden G. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116 (2008) 65-68
38. Gälman C., Lundåsen T., Kharitonenkov A., Bina H.A., Eriksson M., Hafström I., Dahlin M., Amark P., Angelin B., and Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 8 (2008) 169-174
39. Berglund ED, Li CY, Bina HA, Lynes SG, Michael MD, Shanafelt AB, Kharitonenkov A, Wasserman DH: FGF21 controls glycemia via regulation of tissue-specific glucose flux and insulin sensitivity. Endocrinology 2009, doi:10.1210/en.2009-0221. This study reveals the in vivo mechanism by which FGF21 regulates glycemia.
40. Arner P., Pettersson A., Mitchell P.J., Dunbar J.D., Kharitonenkov A., and Rydén M. FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Lett 582 (2008) 1725-1730
41. Moyers J.S., Shiyanova T.L., Mehrbod F., Dunbar J.D., Noblitt T.W., Otto K.A., Reifel-Miller A., and Kharitonenkov A. Molecular determinants of FGF-21 activity - synergy and cross-talk with PPARγ signaling. J Cell Physiol 210 (2007) 1-6
42. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., Takeuchi Y., Fujita T., Nakahara K., Yamashita T., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87 (2002) 4957-4960
43. Larsson T., Nisbeth U., Ljunggren O., Jüppner H., and Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64 (2003) 2272-2279
44. Benet-Pagès A., Orlik P., Strom T.M., and Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14 (2005) 385-390
45. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., Fukumoto S., Tomizuka K., and Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 (2004) 561-568
46. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., Waguespack S., Gupta A., Hannon T., Econs M.J., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112 (2003) 683-692
47. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., and Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291 (2006) E38-49
48. +-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 278 (2003) 2206-2211. This study describes the in vivo mechanisms of FGF21 phosphaturic action.
49. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118 (2008) 3820-3828. Comprehensive review on FGF23 biology.
50. Li S.A., Watanabe M., Yamada H., Nagai A., Kinuta M., and Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 29 (2004) 91-99
51. Farrow E.G., Davis S.I., Summers L.J., and White K.E. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20 (2009) 955-960. This study reveals the localization of FGF23 early action in kidney.
52. Imura A., Iwano A., Tohyama O., Tsuji Y., Nozaki K., Hashimoto N., Fujimori T., and Nabeshima Y. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565 (2004) 143-147
53. Liu S., Vierthaler L., Tang W., Zhou J., and Quarles L.D. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19 (2008) 2342-2350
54. Bai X., Miao D., Li J., Goltzman D., and Karaplis A.C. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145 (2004) 5269-5279
55. Brownstein C.A., Adler F., Nelson-Williams C., Iijima J., Li P., Imura A., Nabeshima Y., Reyes-Mugica M., Carpenter T.O., and Lifton R.P. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 105 (2008) 3455-3460. This study implicates soluble Klotho in the regulation of phosphate levels and parathyroid function.
56. Sitara D., Kim S., Razzaque M.S., Bergwitz C., Taguchi T., Schüler C., Erben R.G., and Lanske B. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 4 (2008) e1000154
57. Pai R., Dunlap D., Qing J., Mohtashemi I., Hotzel K., and French D.M. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 68 (2008) 5086-5095. This study identifies FGF19 as a cancer target.
58. Yamazaki Y., Tamada T., Kasai N., Urakawa I., Aono Y., Hasegawa H., Fujita T., Kuroki R., Yamashita T., Fukumoto S., et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23 (2008) 1509-1518
59. Gutiérrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., Smith K., Lee H., Thadhani R., Jüppner H., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 (2008) 584-592